The burgeoning landscape of emerging treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a similar https://nevezppo938672.governor-wiki.com/1988458/retatrutide_vs_tirzepatide_a_comparative_analysis